1. Home
  2. WRAP vs BMEA Comparison

WRAP vs BMEA Comparison

Compare WRAP & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wrap Technologies Inc.

WRAP

Wrap Technologies Inc.

HOLD

Current Price

$1.61

Market Cap

106.5M

Sector

Industrials

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.73

Market Cap

115.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WRAP
BMEA
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.5M
115.2M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
WRAP
BMEA
Price
$1.61
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
777.0K
1.4M
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
$4,672,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.66
N/A
52 Week Low
$1.04
$0.87
52 Week High
$3.23
$2.99

Technical Indicators

Market Signals
Indicator
WRAP
BMEA
Relative Strength Index (RSI) 49.42 75.92
Support Level $1.46 $1.23
Resistance Level $1.68 $1.69
Average True Range (ATR) 0.15 0.11
MACD -0.01 0.04
Stochastic Oscillator 40.00 72.03

Price Performance

Historical Comparison
WRAP
BMEA

About WRAP Wrap Technologies Inc.

Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: